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A B S T R A C T
Lyme borreliosis in humans is an inflammatory disease affecting multiple organ systems, including the
nervous system, cardiovascular system, joints and muscles. The causative agent, the spirochaete Borrelia
burgdorferi, is transmitted to the host by a tick bite. The pathogenesis of the disease in its early stages is
associated largely with the presence of viable bacteria at the site of inflammation, whereas in the later
stages of disease, autoimmune features seem to contribute significantly. In addition, it has been
suggested that chronic persistence of B. burgdorferi in affected tissues is of pathogenic relevance. Long-
term exposure of the host immune system to spirochaetes and ⁄ or borrelial compounds may induce
chronic autoimmune disease. The study of bacterium–host interactions has revealed a variety of
proinflammatory and also immunomodulatory–immunosuppressive features caused by the pathogen.
Therapeutic strategies using antibiotics are generally successful, but chronic disease may require
immunosuppressive treatment. Effective and safe vaccines using recombinant outer surface protein A
have been developed, but have not been propagated because of fears that autoimmunity might be
induced. Nevertheless, new insights into the modes of transmission of B. burgdorferi to the warm-
blooded host have been generated by studying the action of these vaccines.
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I N T R O D U C T I O N
Lyme borreliosis is an inflammatory disease
caused by the spirochaete Borrelia burgdorferi. This
Gram-negative microorganism is transmitted to a
variety of hosts by ticks, mainly of the genus
Ixodes. Lyme borreliosis in humans manifests as a
multisystem disorder of the skin and other
organs, such as joints, cardiac system, nervous
system and eyes.
Since surveillance for Lyme disease was begun
by the Centers for Disease Control in 1982, the
number of cases reported each year in the USA
has increased dramatically to about 15 000, mak-
ing Lyme disease the most common vector-borne
disease in the USA [1]. In Europe, Lyme borrel-
iosis has been documented widely in forested
areas. The highest frequencies of the disease have
been reported from Scandinavia, Germany, Aus-
tria, Slovenia and Sweden [2]. The infection has
also been reported in Russia, China and Japan.
Ticks of the genus Ixodes undergo larval, nym-
phal and adult stages during their life cycle. The
risk of infection in a given area depends largely
on the environmental density of ticks, their
feeding habits and their animal hosts. Small
mammals, particularly rodents, are important
hosts of ticks and are critical for maintenance of
B. burgdorferi in nature. In addition, deer serve as
hosts, especially during the adult tick stages [3,4].
The predominant tick species that transmit
B. burgdorferi to humans are the Eurasian species
Ixodes ricinus and I. persulcatus, and the North
American species I. dammini, I. pacificus and
I. scapularis [5]. The larval stage of the insect that
emerges from the egg passes through a nymphal
stage before developing into an adult.
The tick feeds only once at each stage in its life
cycle. Activity of the ticks is seasonal. The tick bite
is usually painless, and therefore may go unno-
ticed. Indeed, more than half of affected individ-
uals do not remember a tick bite. During feeding,
the tick may transmit B. burgdorferi through its
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saliva. B. burgdorferi is distributed in the mid-gut
of the infected ticks. It is thought that, once the
tick has its blood meal, B. burgdorferi penetrates
the gut mucosa, disseminates into other tissues,
including the salivary gland, and is inoculated
into the host within 12–72 h [6].
In Europe, the proportion of ticks reported to
harbour B. burgdorferi ranges from 0% to 85%; in
the USA, it varies from 1% to 100%. This
percentage depends on the developmental stage
and the prevalence of infection of the ticks.
Infection is highest in the adult and nymph forms
of the tick, and lowest among the larval forms [7].
Ovarian transmission of B. burgdorferi from the
mother tick to the offspring is possible [8]. Borrelia
can invade the developing oocyte yolk complex in
the ovary from the haemolymph before the
impervious shell forms around the egg [9,10].
During embryonic development, spirochaetes can
migrate from the yolk region to neuronal ganglia.
Ovarian transmission in ticks can be very effi-
cient, with passages over five to nine generations
of ticks having been documented [10].
B I O L O G Y O F B O R R E L I A
B U R G D O R F E R I
The aetiological agent B. burgdorferi sensu lato has
been subdivided into three species causing human
Lyme disease: B. burgdorferi sensu strictu, B. afzelli
and B. garinii. Strains of all three species have been
isolated from patients in Europe, whereas only the
first species has been reported in the USA.
Borrelia spp. vary in length, diameter, tightness
of the coils, and number of periplasmic flagella.
The length can range from 10 to 30 lm and the
width of the helices from 0.2 to 0.25 lm [11].
The generation time under optimal conditions
(30–40C, microaerophilic) is 7–20 h. Ultrastruc-
turally, the causative agent resembles other spiro-
chaetes of the genus Borrelia, with a non-patterned
surface layer, a three-layered outer-membrane
surrounding a periplasmic space containing the
variable number of flagella, and the protoplasmic
cylinder [12] (Fig. 1).
B. burgdorferi has a linear chromosome in
addition to linear and circular plasmids. The
genes that encode major outer-surface proteins
(Osps) are located on plasmids [13]. B. burgdorferi
strains usually have three major Osps (OspA,
OspB, OspC) [13], along with OspD [14], OspE,
OspF [15] and OspG.
The loose association of the outer-envelope
with the underlying protoplasmic cylinder leads
to the separation of the cell components when
borrelia are kept in hypotonic solution [16]. This
so-called bleb formation has been observed on the
outer-envelope of Borrelia in vitro when a specific
antibody or complement is added [17] (Fig. 1).
Studies have indicated that exposure to physio-
logical stress, e.g., changes in pH, depletion of
metabolites and ageing [17], or exposure to
antibiotics [18,19], can lead to bleb formation.
Little is known about the physiological role of
these forms, although blebs and gemmae have
been shown to contain DNA [20] and may be
involved in the exchange of genetic information.
Alban et al. [21] reported that serum starvation
resulted in the transformation of motile helical
forms into non-motile, spherical cysts containing
tightly coiled spirochaetes. Addition of tetracyc-
line inhibited the formation of cysts, demon-
strating that cyst formation requires protein
synthesis. Unlike cyst forms, blebs and gemmae
have not been shown to be viable, and seem to be
incapable of transforming back into motile veget-
ative bacteria [21]. Cysts have been observed in
human cerebrospinal fluid (CSF) [22] and in the
tissues of patients infected with Lyme disease
[23,24]. Thus, if viable cysts can form in the
human body, they may represent a strategy that
facilitates the survival of B. burgdorferi during
Fig. 1. Transmission electronmicrograph of Borrelia burg-
dorferi strain sensu strictu showing the corkscrew shape and
motility, and the outer-membrane surrounding a periplas-
mic space that contains the variable number of flagella and
the protoplasmic cylinder. Insert: Immuno-electronmicro-
graph using a polyclonal antiserum against Borrelia burg-
dorferi, demonstrating that a bleb formed during in-vitro
culture is an integral part of the bacterial cell.
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nutritionally adverse conditions in host tissues.
By forming cysts, it is also conceivable that
B. burgdorferi might evade detection by the host
immune system [21]. Hulinska et al. [24] demon-
strated that the surface of cysts found in erythema
migrans of infected human tissue was non-react-
ive to antibodies against OspA, whereas the
content of the cysts did react with OspA [24].
Periplasmic flagella can be found beneath the
outer-membrane, and these mediate spirochaete
motility. Borrelial flagella resemble one another
and basically have the same structural organisa-
tion as the flagella of other eubacteria [25]. Like
other spirochaete flagella, borrelial flagella also
insert sub-terminally and with bipolarity. Differ-
ent Borrelia spp. have different numbers of flagella
[26]. The flagella have four components—the
filament, the hook, the neck and the basal disk
[27]—and resemble flagella of Gram-negative
bacteria [28]. While treponemal flagella are
sheathed, borrelial flagella are characteristically
unsheathed [29] and are composed predomin-
antly of flagellin protein with a molecular mass of
41 kDa [30].
The borrelial cell membrane contains muramic
acid [31] and ornithine as a diamino acid in a
peptidoglycan structure [32]. A unique feature of
Borrelia spp. is that the genes for the immuno-
dominant outer-surface proteins OspA, OspB and
OspC are located on plasmids. Although the
outer-surface proteins are immunologically and
genetically variable [33], OspA [34] and OspC [35]
have proven to be very useful proteins for the
development of a Borrelia vaccine. Other import-
ant antigens of B. burgdorferi are the flagellin
protein and a 60-kDa antigen. The latter has been
termed a common antigen and belongs to the
heat-shock protein family. The flagellin protein
and the 60-kDa antigen are not species-specific.
The complete genome of B. burgdorferi sensu
strictu (strain B31) has now been sequenced [3].
The genome is quite small (c. 1.5 Mb) and consists
of a highly unusual linear chromosome of 950 kb,
together with nine linear and 12 circular plas-
mids. The outer-surface proteins of B. burgdorferi
presumably help the spirochaete to adapt to and
survive in markedly different environments
between cold-blooded ticks and mammals [4].
B. burgdorferi undergoes dramatic metamorpho-
sis, including changes in expression of many
different lipoproteins, when it transfers from the
tick to the mammalian environment. Inside the
mid-gut of unfed ticks, B. burgdorferi expresses the
OspA lipoprotein in large amounts [36]. Immu-
nofluorescence studies have shown that after the
tick attaches to the mammalian host and begins
feeding, B. burgdorferi starts to down-regulate
OspA expression, and rapid synthesis of OspC
begins [37]. At the same time, B. burgdorferi
migrates from the tick mid-gut to the salivary
glands in preparation for mammalian host infec-
tion. Once B. burgdorferi is inside the mammalian
host, the transition from OspA to OspC expres-
sion is complete. Now B. burgdorferi no longer
expresses OspA, while OspC is detectable readily
on spirochaetes that have adapted to the mam-
malian host [38].
Temperature adaptation is one important factor
that B. burgdorferi uses to undergo this transition.
Changes in lipoprotein expression can also be
demonstrated by comparing B. burgdorferi grown
in culture at 23–24C with that grown at 35C [37].
The effects of temperature on the differential
expression of OspA and OspC are enhanced by
co-cultivation of B. burgdorferi with tick cells [39].
In addition to OspC, other lipoproteins are also
up-regulated during the transition to the warm-
blooded mammalian host. Thus, when culture
conditions are changed from low to high temper-
atures, up-regulated expression of the two outer-
surface proteins OspE and OspF can be observed
[40]. It has become evident that spirochaetal
proteins, up-regulated during infection of mam-
mals, are members of a large family of OspE- and
OspF-related proteins, currently designated Erps
[41]. Further studies have shown that expression
of Erp proteins can be induced in the cultivated B.
burgdorferi strain B31 by a shift in temperature
from 23C to 35C [40].
Incubation of spirochaetes at different temper-
atures is one method of mimicking environmental
signals that can regulate lipoprotein expression.
In addition, another surface-exposed lipoprotein
has been reported to undergo extensive antigenic
variation during early disseminated infection [42].
The genome does not contain any homologue for
the system that enables the organism to secrete
toxins and other virulence factors. So far, the only
known virulence factors of B. burgdorferi are
surface proteins that allow the spirochaete to
attach to mammalian cells. The organism produ-
ces few proteins with biosynthetic activity, and
apparently depends on the host for many of its
nutritional requirements.
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C L I N I C A L F E A T U R E S O F L Y M E
D I S E A S E
Lyme borreliosis in adults can be divided into
three clinical stages [43–45] that may overlap with
each other. The first two stages, which appear
within a few weeks or months after infection with
B. burgdorferi, represent the early phase of the
disease. The third, or late, phase appears after
several months or years [46]. The early features of
the disease are usually self-limiting, but late
features may become chronic and progressive.
Previous exposure to B. burgdorferi does not
prevent infection; indeed, the occurrence of ery-
thema migrans in a patient with acrodermatitis
chronica atrophicans has been reported [44].
Stage I: Early infection
In the early stage of infection, erythema migrans
develops regularly, but can be absent in up to 50%
of patients (for details of the clinical morphology,
see [45]). The skin lesion is frequently accompan-
ied by influenza-like symptoms, such as malaise,
fatigue, headache, fever and regional lymphaden-
opathy. In Europe, erythema migrans often
remains an indolent localised infection, whereas
in the USA this lesion has been associated with
more intense inflammation and signs that often
suggest early dissemination of the spirochaete
[47]. In one study, spirochaetes could be cultured
from plasma samples in 50% of patients affected
with erythema migrans [48]. The lymphocytoma,
another acute skin lesion, appears typically on the
nipple or areola of the breast [49], or on the ear
lobes [45]. These lesions are usually caused by
B. afzelli or B. garinii [50], and are therefore
reported mainly in Europe, but not in the USA.
A few weeks to months after infection, several
organs may become affected, probably because of
haematogenous spread of the pathogen.
Stage II: Early dissemination
After a tick bite, B. burgdorferi might spread from
the site of the bite into the bloodstream, causing
clinical signs of early dissemination. Lyme
disease can affect the nervous system. Neural
manifestations during this stage are meningoradi-
culoneuritis (Bannwarth’s syndrome), meningitis,
plexus neuritis, cranial neuritis (predominantly
involving facial nerves) and mononeuritis
multiplex. Bannwarth’s syndrome, which in Eur-
ope is the most common neurological manifesta-
tion in adults, is characterised by CSF lymphocyte
pleocytosis and intense radicular pain. The
spread of B. burgdorferi within the nervous system
has been demonstrated in non-human primates
[51], the only known model of neuroborreliosis. In
immunocompromised monkeys, which have a
larger spirochaetal burden than immunocompe-
tent animals, B. burgdorferi has been shown to
infiltrate leptomeninges, sensory and motor nerve
roots, and the dorsal root ganglion, but not the
brain parenchyma [52]. In the peripheral nervous
system, spirochaetes have been detected in the
perineurium, the connective tissue sheath sur-
rounding each bundle of peripheral nerve fibres.
Few patients suffering from Lyme disease
develop heart problems. Most commonly, atrio-
ventricular blockage has been described, and
occasionally acute myopericarditis or mild left
ventricular dysfunction, but rarely cardiomegaly
[43]. These heart abnormalities can appear several
weeks after infection. In Europe, B. burgdorferi has
been isolated from endomyocardial biopsy sam-
ples from several patients with chronic dilated
cardiomyopathy [53].
Arthralgia and myalgia indicate early musculo-
skeletal involvement. Frank arthritis and myositis
can also be observed occasionally in the first few
months of the disease. Regional lymphadenopathy
and generalised lymphadenopathy may develop.
Stage III: Chronic disease
Chronic organ involvement may develop years
after the tick bite. Skin and soft tissue manifesta-
tions are common in Lyme borreliosis [45]. Acro-
dermatitis chronica atrophicans starts as an
inflammatory dermatitis. Later, this lesion evolves
into an atrophic skin lesion.
Among untreated patients in the USA, c. 60%
begin to have intermittent attacks of joint swelling
and pain. Large joints, especially the knees, are
primarily affected [54]. Synovial tissue from
affected patients shows synovial hypertrophy,
vascular proliferation and marked infiltration of
mononuclear cells. Furthermore, patients with
Lyme borreliosis usually have higher Borrelia-
specific antibody titres in serum than do patients
with any other manifestation of the disease. After
several short attacks of arthritis, some patients
may develop persistent joint inflammation.
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Direct involvement of the eye (keratitis, optic
neuritis) has also been attributed to B. burgdorferi
infection [43,55]. However, since B. burgdorferi has
been isolated rarely from patients with these
opthalmological disorders, the pathogenesis in
these cases is uncertain.
In both the USA and Europe, a chronic axonal
polyneuropathy may develop, manifested pri-
marily as spinal radicular pain [56,57]. Electromy-
ograms typically show diffuse involvement of
proximal and distal nerve segments. In Europe,
B. garinii may cause chronic encephalomyelitis,
characterised by cranial neuropathy with marked
intrathecal production of antibodies against the
spirochaetes [56]. In the USA, a mild late neuro-
logical syndrome has been reported, termed
Lyme encephalopathy. It is characterised by
memory deficit, minor depression, irritability
and somnolence [58–61].
The differences between genospecies found in
Europe and North America may account for
differences in the frequencies of certain manifes-
tations of Lyme disease in these areas. For
example, neurobiological manifestations of Lyme
disease are more common in Europe, whereas
rheumatological manifestations are more com-
mon in North America.
Perinatal Lyme disease
Case reports have suggested that adverse out-
comes of pregnancies may be complicated by
maternal Lyme borreliosis [62]. The risk of trans-
placental transmission of B. burgdorferi is probably
minimal when appropriate antibiotics are given to
a pregnant woman with Lyme borreliosis. There
have been several published case series investi-
gating the relationship between gestational Lyme
disease and fetal outcome. The questions
addressed in these series were as follows. Does
B. burgdorferi cross the placenta and invade the
foetus? If there is transplacental transmission,
does this have any significance for the develop-
ment of the foetus? Several studies have shown a
relationship between seropositivity in pregnancy
and pregnancy outcome. A large serological study
of 2014 women, of whom 12 were seropositive,
revealed no increased risk of congenital malfor-
mations, low birth weight, abnormal length of
gestation or risk of fetal death among children
born to seropositive mothers [63]. A second study
of 1416 pregnant women, of whom 12 were
seropositive at delivery, also revealed no adverse
outcomes attributable to seropositivity [64]. A
study comparing 5000 infants, divided equally
between a Lyme-endemic area and a control area,
showed no significant differences in the incidence
of congenital malformations, except for a statisti-
cally significant increase in the rate of cardiac
malformations in the Lyme-endemic area [65].
However, it is not known whether this finding
represents an artefact or a valid difference
between the two populations. A further epidemi-
ological study conducted in a Lyme-endemic area
has questioned the connection between maternal
Lyme disease and congenital heart disease [66]. In
this study of 796 patients and 704 control subjects,
there was no significant association between
congenital defects and maternal Lyme disease.
In another clinical study, a higher incidence of
neurological disorders was not found in children
of women with gestational Lyme disease in an
epidemic area.
Studies in both human and animal models have
established that B. burgdorferi can cross the pla-
centa, presumably during the period of initial
spirochaetaemia. Despite documentation of trans-
placental transmission of B. burgdorferi, there has
been no clinical evidence for a fetal inflammatory
or immune response, or an adverse neonatal
outcome resulting from gestational Lyme disease
[67]. The above studies indicated that an adverse
fetal outcome resulting from maternal infection
with B. burgdorferi at any point during pregnancy
in humans is, at most, extremely rare.
Lyme disease in children
In principle, manifestations among children are
the same as in adults. However, Lyme disease in
children follows a somewhat different course and
has different symptoms than in adults (Table 1).
In most cases, the clinical and epidemiological
features are comparable among children suffering
from Lyme disease in Europe and the USA [68,69].
Children account for a relatively high number of
Lyme borreliosis patients, presumably because of
greater exposure to ticks and decreased attention
to prevention of Lyme disease. Frequently, tick
bites in children occur on the upper parts of the
body, and especially on the head. Thus, modes of
pathogen dissemination inside the host, especially
into the central nervous system, might occur faster
than in adults. This is reflected by the fact that
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meningitis in children occurs frequently early in
the course of the disease, and often in parallel with
erythema migrans. Lymphocytic meningitis, with
or without cranial neuropathy, is the major early
neurological manifestation of Lyme disease in
children, and generally presents with episodic
headache, mild neck stiffness, numbness and poor
motor co-ordination.
Eppes et al. [70] compared Lyme meningitis with
viral meningitis in children. Like Lyme meningitis,
viral meningitis occurs during summer, and is
difficult to diagnose in Lyme-endemic regions, but
it was suggested that some clinical and laboratory
findings in Lyme meningitis are sufficiently dis-
tinctive: (1) cranial neuropathy, especially periph-
eral seventh nerve palsy, is strong evidence of
Lyme meningitis; (2) papilloedema is more likely to
be seen in Lyme meningitis than in viral menin-
gitis; (3) a longer duration of symptoms before
hospital admission supports a diagnosis of Lyme
meningitis; (4) fever at the time of diagnosis is more
likely to be related to viral meningitis; and (5) CSF
pleocytosis is less pronounced in Lyme meningitis
than in viral meningitis, and especially the initial
neutrophilic component [70]. Chronic late stage
neurological disease, e.g., meningoradiculoneuri-
tis or encephalomyelitis, is rare and is not as
frequent as joint disease [62].
Lyme borreliosis may be the cause of a variety
of inflammatory changes of the eye occurring in
childhood, either early (conjunctivitis) or late
(uveitis, keratitis) [55]. In a German study of
84 children with arthritis caused by late Lyme
borreliosis, three had borrelial eye disease, inclu-
ding keratitis, anterior uveitis and uveitis inter-
media [71]. Clinicians should be aware that optic
nerve involvement may be a manifestation of
Lyme disease, because of either inflammation or
increased intracranial pressure, or both [55].
Among patients with symptoms suggestive of
Lyme disease, decreased vision suggests the
possibility of optic neuritis, whereas the presence
of headache, visual symptoms, pulsatile tinnitus,
sixth nerve palsy or papilloedema can be import-
ant signs of increased intracranial pressure. A few
children in the USA have been reported with optic
neuritis associated with Lyme disease, which
occurred 1–9 months after initial infection
[55,72–75].
Younger children (aged < 10 years) are more
likely to have fever at onset of arthritis, followed
by an acute or episodic course, and to have lower
antibody titres to B. burgdorferi compared to adults
[76,77]. It has been documented that the clinical
characteristics of children with Lyme arthritis
vary with age. Among adults with Lyme arthritis,
Table 1. Comparison of Lyme dis-
ease manifestations in children and
adults
Course of disease Children Adults
Early manifestations (days to a few weeks)
General symptoms Influenza-like disease Influenza-like disease,
lymphadenopathy
Skin Erythema migrans, lymphocytoma Erythema migrans, lymphocytoma
Neurological Lymphocytic meningitis
Cranial neuritis, mainly the facial
nerve
Heart Myopericarditis
Eye Conjunctivitis
Joint; muscle Arthralgias
Early dissemination (after a few weeks)
General symptoms Lymphadenopathy
Neurological Meningitis
Meningoradiculoneuritis
(Bannwarth’s syndrome)
Plexus neuritis, cranial neuritis
Mononeuritis multiplex
Heart Atrioventricular blockage
Myopericarditis, cardiomyopathy
Joint; muscle Arthralgia, myalgia, oligoarthritis
Late stage of infection, chronic disease (months to years after infection)
Skin Acrodermatitis chronica
atrophicans (rare)
Acrodermatitis chronica atrophicans
Neurological Meningoradiculoneuritis (rare) Axonal, sensory polyneuropathy
Encephalomyelitis (rare) Cranial neuropathy
Chronic encephalomyelitis,
encephalopathy Cardiomyopathy (rare)
Heart Cardiomyopathy
Eye Uveitis, keratitis Retinitis, uvetis, keratitis,
endophthalmitis
Joint; muscle Episodic or chronic oligoarthritis Treatment-resistant arthritis
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c. 10% are reported to develop chronic arthritis. In
children with Lyme arthritis, a chronic course of
arthritis seems less frequent [78,79]; however, in a
European study, 24% of children affected by Lyme
arthritis retained manifestations of disease, inclu-
ding arthritis and arthralgias, 12 months after
antibiotic treatment [76]. In contrast to adult
patients, temporomandibular or sternoclavicular
joint involvement is rare in children.
P A T H O G E N E S I S
Pathogenic factors encoded by spirochaetes
Most of the sub-surface lipoproteins of B. burg-
dorferi play an important role in cellular physiol-
ogy and participate directly in pathogenesis
[3,80]. Mutants deficient in OspA are more sen-
sitive to complement lysis and digestion by
proteases in the mid-gut of ticks [81,82]. These
facts suggest that OspA expression by B. burgdor-
feri during tick infection might protect the organ-
ism both from tick mid-gut proteases and from
mammalian complement when the tick takes
blood from the host. The ability of spirochaetes
to attach to eukaryotic cell surfaces and extracel-
lular matrix proteins is also essential in patho-
genesis.
Several pathogenic mechanisms may aid in the
dissemination of B. burgdorferi. For example, the
sequences of OspC differ considerably among
Borrelia strains, and only a few particular se-
quences have been associated with dissemination
of disease [83]. Spread through skin and other
tissue matrices may be facilitated by the binding
of human plasminogen and its activators to the
surface of the spirochaete [84]. During the dis-
semination and homing of B. burgdorferi to specific
sites, the pathogen attaches to certain host inte-
grins [85], matrix glycosaminoglycans [86] and
extracellular matrix proteins [87].
Decorin is a collagen-associated glycosaminog-
lycan found in various tissues, including skin and
joints, i.e., sites typically associated with Lyme
disease. B. burgdorferi has been shown to attach
selectively to decorin, which led to the subsequent
isolation of decorin-binding protein (Dbp) genes
by screening an expression library with digoxige-
nin-labelled decorin [86,88]. The two gene oper-
ons encoding the lipoprotein DbpA and the
related DbpB were identified independently by
screening a B. burgdorferi expression library
[89,90] and by sequencing DbpA found in
B. burgdorferi outer-membranes [91]. Borrelia dec-
orin-binding proteins A and B bind decorin on
collagen fibrils, which may explain why the
organism is commonly aligned with collagen
fibrils in the extracellular matrix of the heart,
nervous system and joints. In a recent report,
decorin-deficient mice had more limited spiro-
chaetal colonisation of joints, and milder arthritis,
than normal mice of the same strain that
expressed decorin [92]. DbpA demonstrates con-
siderable heterogeneity among B. burgdorferi
strains. Chemical modification of lysine residues
was found to abrogate DbpA binding to decorin.
Involvement of the infected host
Several studies have suggested that B. burgdorferi
is present at the site of inflammation in many
clinical manifestations of Lyme disease. B. burg-
dorferi does not produce toxins, but is a potent
immunomodulator. The effects of B. burgdorferi on
local cells may lead to suppression of the local
immune response. A decrease in the expression of
major histocompatibility complex (MHC) markers
on Langerhans’ cells in the skin of patients with
acrodermatitis chronica atrophicans has been
demonstrated after contact with Borrelia [93].
B. burgdorferi infection has been shown to
increase the expression of neural cell adhesion
molecule on endothelial cells in comparison with
controls [94]. After B. burgdorferi has entered the
skin, it can move through the extracellular matrix.
B. burgdorferi can bind to the components of the
extracellular matrix, including epithelial cell-
derived proteoglycans, by interacting with deco-
rin [88], glycosaminoglycans [95] and fibronectin
[96,97]. Many studies have shown that B. burg-
dorferi can attach to human umbilical vein endot-
helial cells (HUVECs) in vitro, and that it can
traverse HUVEC monolayers grown on tissue
substrate. This penetration may be either between
or through the HUVECs [98]. HUVECs exposed to
B. burgdorferi in in-vitro culture show increased
expression of E-selectin, vascular cell adhesion
molecule and intercellular cell adhesion molecule.
Other resident joint and vascular endothelial
cells seem to react differently. Synovial fibroblasts
have been shown to down-regulate intercellular
cell adhesion molecule-1 after contact with
B. burgdorferi. Vascular cell adhesion molecule
expression was not changed in these cells after
604 Clinical Microbiology and Infection, Volume 10 Number 7, July 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 598–614
infection with B. burgdorferi. In addition, the
expression of nitric oxide synthase was not altered
by the infection [99]. It is of particular interest that
synoviocytes strongly up-regulate these molecules
during an inflammatory response. Thus, these
local immunomodulatory features might be
sequelae of B. burgdorferi residing, or even persist-
ing, in the cytosol of resident joint cells, as has been
demonstrated in vitro (Fig. 2) [100]. However,
intracellular persistence of a spirochaete has not
so far been demonstrated consistently in vivo.
Despite robust humoral and cellular immunity
against B. burgdorferi in most patients, the disease
can become chronic, even after several courses of
antibiotic treatment. The pathogenesis of chronic
Lyme disease remains a topic of discussion,
currently focusing on the concepts of persistent
infection and ⁄ or autoimmunity. Recently, chronic
joint inflammation has been attributed to autoim-
munity [101,102].
There is strong evidence that T-lymphocytes
play a major role in the pathogenesis of Lyme
arthritis. It has been shown that the proliferative
response of B. burgdorferi-specific T-lymphocytes
isolated from the synovial fluid or peripheral blood
of adults [103–107] and children with Lyme arth-
ritis [108,109] is elevated. In addition, T-lympho-
cytes from individuals with prolonged Lyme
arthritis responded more vigorously to stimulation
with B. burgdorferi antigens than the T-lymphocytes
from adult individuals affected by less progressive
forms of Lyme arthritis [110,111]. Likewise, cloned
T-lymphocytes from a patient with chronic Lyme
arthritis exhibited enhanced proliferative
responses to various B. burgdorferi antigens [112].
Many investigators have demonstrated that
individuals with progressive forms of Lyme
arthritis frequently have T-lymphocytes that lib-
erate lymphokines characteristic of the Th1 phe-
notype [112,113]. The existence of highly
polarised Th1 lymphokine patterns has also been
described in mice infected with B. burgdorferi.
Other studies [114–116] have shown a relation-
ship between T-cell phenotypes and the induction
or control of Lyme arthritis. T-cell involvement in
the pathogenesis of Lyme arthritis has been
described in a hamster model of Lyme borreliosis.
Lymph node T-cells from hamsters vaccinated
with 108 formaldehyde-inactivated spirochaetes
in adjuvant are able to confer susceptibility to
severe Lyme arthritis when transferred into naive
hamsters challenged with 106 viable B. burgdorferi
cells [114]. When primed T-cells were infused
into naive recipients and challenged with dead
B. burgdorferi, no arthritis was seen [114].
These studies suggest that gene products
expressed actively by the spirochaete inside a
mammalian host might be involved in the propa-
gation of Lyme arthritis mediated by T-cells [117].
Hence, T-cells seem to be responsible for the
development of destructive Lyme arthritis [118].
However, protection from disease by CD8+ T-cells
has been reported [116].
In the initial phases of disease, humoral
immune responses in general are limited, or at
least specific antibodies are hard to detect [119].
B-cell reaction to the pathogen might be abro-
gated by early antibiotic treatment [120]. There-
fore, serological testing after early antibiotic
treatment of erythema migrans is mostly unre-
markable and is not recommended [121]. In the
chronic phases of disease, a robust B-cell response
against a variety of Borrelia epitopes is generally
detectable [122] and can be used for serodiagno-
sis. However, this humoral response seems not to
be protective, since it cannot prevent reinfection
of the host with B. burgdorferi. Children and adults
do not differ in their antibody response against
B. burgdorferi [123]. The role of the B-cell response
and antibody production in the pathogenesis of
chronic Lyme disease is still to be elucidated.
It is well-established that T-lymphocytes of the
Th1 phenotype are involved in the activation of
Fig. 2. Transmission electronmicrograph of a human
synovial cell infected with Borrelia burgdorferi in vitro,
demonstrating an intracellular cytosolic location of the
spirochaetes, identified by multiple corkscrew-shaped
structures in the cytosol.
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macrophages [124]. Macrophage activation may be
central to the induction of Lyme arthritis [125,126].
Elevated levels of various macrophage-derived
molecules (interleukin-1, tumour necrosis factor,
prostaglandin E2 and collagenase) have been
detected in synovial fluid extracts and serum from
individuals with Lyme arthritis [127–130]. Inter-
leukin-1 and tumour necrosis factor are known to
activate osteoclastic cartilage and bone reabsorp-
tion, and may be responsible for the clinical and
pathological manifestations of Lyme arthritis [131].
Macrophages can also be stimulated with B. burg-
dorferi to produce nitric oxide [132]. Production of
nitric oxide has been associated with the induction
of other arthritic diseases [133,134].
Autoimmune features of Lyme disease
One potential explanation for antibiotic-resistant
Lyme disease is the generation of autoimmunity
directly or indirectly mediated by the pathogen
and based on molecular mimicry. Gajdusek [135]
has suggested that axonopathy in a variety of
neurological diseases might result from anti-
axonal antibody production, and anti-axonal
IgM antibodies have been demonstrated in the
serum of patients with neurological Lyme disease
[136]. Genetic linkage studies in adults with Lyme
arthritis have demonstrated a link with MHC
class II molecules DR2 and DR4 [137]. In addition,
these patients develop anti-OspA antibodies cor-
relating with the duration of their arthritis [138],
suggesting that OspA may be involved in the
autoimmune process. Self-reactive T-cells may
maintain local inflammation [139].
MHC class II molecules play a critical role in
the activation of the immune system. Polymor-
phisms within the genes encompassing the MHC
class II structure influence the immune system by
at least two mechanisms. First, polymorphic
amino-acid residues on distinct class II proteins
determine whether or not an individual peptide
will bind and therefore be presented by a partic-
ular class II molecule displayed on an antigen-
presenting cell. Second, MHC class II molecules
regulate the developmental selection of T-cell
receptor specificity in the thymus, thereby affect-
ing the repertoire of CD8+ and CD4+ T-cells that
recognise foreign peptides in the context of MHC
class II molecules [117,140].
The first indication that treatment-resistant
Lyme borreliosis might be an autoimmune dis-
ease came from a study analysing MHC II alleles
(HLA-DR4) in patients with Lyme arthritis of
brief, moderate or chronic duration [141]. Patients
with chronic treatment-resistant Lyme arthritis
have been found to have MHC II alleles that are
also associated with rheumatoid arthritis, partic-
ularly HLA-DRB1* 0401 and 0101 alleles [142].
Most macrophages are able to internalise B. burg-
dorferi [143–147], and many investigators have
demonstrated the localisation of intracellular
B. burgdorferi within well-defined phagolyso-
somes [146,148,149] (Fig. 3). Filgueira et al. [150]
showed that borrelial antigens were co-localised
with MHC class P molecules within lysosomal
vesicles of dendritic cells. These studies suggest
that Borrelia antigens are loaded on to MHC class
P molecules and are presented subsequently to
CD4+ T-lymphocytes.
It is of interest that synovial fibroblasts, which
harbour B. burgdorferi in vitro, are able to present
not only MHC I but also MHC II molecules
[99,100]. Gross et al. [101] suggested that LFA-1
can serve as a cross-reactive autoantigen for
OspA-reactive Th1 cells, leading to treatment-
resistant Lyme arthritis. This was the first time
that criteria for an autoimmune disease caused by
molecular mimicry of microbial epitopes were
Fig. 3. Transmission electronmicrograph of a human per-
ipheral blood monocyte, showing conventional phagocy-
tosis of a Borrelia burgdorferi strain sensu strictu in a large
central and smaller phagolysosome at the bottom of the
figure.
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demonstrated in treatment-resistant Lyme arthri-
tis [101,102,151–153]. Fig. 4 summarises these
findings schematically, and suggests the possibil-
ity that intracellular persistence of B. burgdorferi in
synovial cells might contribute to this scenario of
molecular mimicry.
These studies were supported by the analysis of
molecular mimicry in chronic neuroborreliosis.
Hemmer et al. [154] demonstrated elegantly that
several T-cell clones were responding to Borrelia
peptides and endogenous host peptides. So far,
these data on autoimmunity have been generated
from adult Lyme disease patients. Comparable
data on the pathogenesis of Lyme disease in
children are pending.
Coiling phagocytosis has also been described as
a mechanism for internalisation of B. burgdorferi
[150,155–157] (Fig. 5). Coiling phagocytosis
results in cytosolic deposition of antigens [150,156]
and has been suggested as a mechanism for MHC
class I presentation of exogenous antigens [158].
The presence of cytosolic B. burgdorferi has also
been documented within human macrophages
and granulocytes [156]. Likewise, an intracellular
location of B. burgdorferi has been described for
human dendritic cells [150], fibroblasts and syn-
ovial cells (Fig. 2) [100,159], endothelial cells [160]
and murine marophages [146]. The ability of spiro-
chaetes to enter the cytoplasm of macrophages
may result in MHC class I presentation of Borrelia
antigens to CD4– CD8+ T-lymphocytes. In support
of this, Busch et al. [116] demonstrated the exist-
ence of B. burgdorferi-specific CD8+ T-lympho-
cytes in patients with Lyme borreliosis in
remission. These studies suggest that B. burgdor-
feri-specific CD8+ and CD4+ T-lymphocytes can
participate in the pathogenesis of Lyme arthritis.
D I A G N O S I S O F L Y M E D I S E A S E
The diagnosis of Lyme disease is based usually on
recognition of the characteristic clinical features
and a history of exposure in an area where the
disease is endemic. For the diagnosis of an
infectious disease, the standard is isolation
of the causative agent in culture. Culture of
B. burgdorferi from different specimens in Bar-
bour–Stoenner–Kelly medium would permit a
definitive diagnosis. However, positive cultures
have generally only been obtained early in the
course of disease, primarily from biopsy samples
of erythema migrans lesions, less often from
plasma samples [48], and only occasionally from
CSF of patients with acute meningitis or facial
paralysis [161]. At a later stage of the infection,
PCR testing is greatly superior to culture for
detection of B. burgdorferi in synovial fluid [162].
B. burgdorferi has not been isolated from the CSF
of patients with chronic neuroborreliosis, but
B. burgdorferi DNA has been detected in CSF from
a limited number of these patients [163].
The serological tests used most commonly to
diagnose B. burgdorferi infection include enzyme-
linked immunosorbent assay, indirect immunoflu-
orescence assay and Western blotting [164]. In
TH CD4+
Antigen
presenting
cell
Antigen
presenting
cell
Induction of T-cells reactive against
Presentation of OSP-A derived
Borrelia peptide (165-173)
by HLA DRBI *0401
Presentation of LFA-Ia
derived selfpeptide (332-340)
by HLA DRBI *0401
Borrelia-peptide OSP-A (165-173)
and
selfeptide LFA-la (332-340)
presented by HLA DRBI *0401
Fig. 4. Molecular mimicry in Lyme arthritis, depicting
antigen-presenting cells (in this case monocytes, macroph-
ages, dendritic cells and synovial fibroblasts) presenting
peptides generated from borrelial OspA and host LFA-Ia
(human leucocyte function-associated antigen 1), which
induce a cross-reactive T-cell response.
Fig. 5. Coiling phagocytosis of Borrelia burgdorferi by a
cluster of human peripheral blood monocytes with their
borders outlined in the scheme. The central cell shows
multiple coiling phagocytosis figures probably trying to
engulf one single spirochaete.
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most cases, serological findings are dependent on
the duration of the disease and clinical manifesta-
tions. In the early stages, < 50% of patients have
detectable antibodies, predominantly IgM. In the
late stages, seropositivity rises to 70–90%, with a
shift from IgM to IgG antibodies. An antibody
response to B. burgdorferi analysed by enzyme-
linked immunosorbent assay and Western blot-
ting, and interpreted according to the criteria of the
Centers for Disease Control, is the current standard
for diagnosis of Lyme disease [122]. In Europe,
three different strains of B. burgdorferi contribute to
the disease, in contrast to one strain in the USA. No
single set of criteria for the interpretation of
immunoblots results in a high level of sensitivity
and specificity in all European countries [165], and
antibiotic therapy may prevent an increase in
specific antibodies. However, seroconversion
may still occur after antibiotic therapy. Thus, if
antibody titres are negative in early Lyme borrel-
iosis, repetition of the tests has been recommended
after c. 4 weeks [164]. In chronic disease, IgG
antibody titres are usually high, and may remain so
for several years, even after successful treatment.
Rarely, patients with chronic disease remain sero-
negative, showing only a cell-mediated immune
response to B. burgdorferi [166].
One possible cause of seronegativity is the
formation of immune complexes by antigen-spe-
cific antibodies [167]. The great variability in
serological test results between laboratories may
be associated with differences in the test proce-
dures used, different diagnostic cut-off values for
the discrimination of positive or negative values,
and different antigen preparations or strains of
B. burgdorferi used to prepare the test. Western
blotting has been recommended as a confirmatory
test [168], but interpretation is often difficult
because specific and cross-reactive bands can
often appear close together. A promising
approach to standardise Western blots is the use
of a defined panel of recombinant antigens [169].
T R E A T M E N T O F L Y M E D I S E A S E
Most patients treated for Lyme borreliosis have
an excellent prognosis, although some patients
treated for erythema migrans in recent series
continue to have a variety of complaints after
antibiotic therapy. One recent study in New
England, USA, found that most Lyme borreliosis
patients who were not feeling well 3 months after
treatment had laboratory evidence of coinfection
with Babesia spp. [170]. Patients with carditis and
neurological disorders also tend to do well after
treatment, although some adult patients have
residual neurological deficits such as mild sev-
enth cranial nerve palsy after treatment [171].
Oral doxycycline or intravenous ceftriaxone are
usually effective in the treatment of Lyme arthri-
tis, in combination with non-steroidal anti-inflam-
matory drugs [172]. If arthritis persists despite the
completion of two courses of antibiotic therapy,
intra-articular steroids, disease-modifying anti-
rheumatic drugs or arthroscopic synovectomy
may be introduced. After appropriate treatment
of Lyme disease, a small percentage of adult
patients continue to report subjective symptoms
such as musculo-skeletal pain, neurocognitive
difficulties, or fatigue that may last for years.
This disabling syndrome has been termed post-
Lyme disease syndrome. Clinically, it resembles
chronic fatigue syndrome or fibromyalgia [173]. It
occurs more frequently in adult patients with
symptoms suggestive of early dissemination of
the spirochaete into the nervous system, and
particularly if treatment was delayed [174].
Treatment of Lyme disease in children is
comparable to recommendations established for
adult disease [175]. Doxycycline, however, should
not be used in the treatment of children aged
< 10 years. Early manifestations (except cardiac or
neurological involvement) are treated with oral
amoxycillin (50 mg ⁄ kg ⁄day) or oral doxycycline
(100 mg ⁄day in two doses) for 14–21 days.
Meningitis, meningoradiculitis, cardiac manifes-
tations, Lyme arthritis and chronic treatment-
resistant arthritis are treated with intravenous
ceftriaxone 50–75 mg ⁄ kg ⁄day once-daily for
14 days. Alternatively, intravenous cefotaxime
(150–200 mg ⁄ kg ⁄day) for 14 days, oral amoxy-
cillin (50 mg ⁄kg ⁄day) or oral doxycycline
(100–200 mg ⁄day in two doses) for 30 days may
be used [77].
P R E V E N T I O N O F L Y M E D I S E A S E
Avoid tick bites
Hikers can reduce exposure to ticks by walking
wide trails. Preferred dress is light-coloured
clothing (to make recognition and removal of
the ticks easier), with long sleeves that are tight at
the wrists and long trousers that are tucked into
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light-coloured socks. A hat should be worn in
densely wooded areas [176]. Habitats that are
heavily infested with ticks, such as wooded areas,
should be avoided if possible.
Tick and insect repellents that contain
n,n-dimethylmetatoluamide applied to the skin
provide additional protection, but require reap-
plication every 1–2 h for maximum effectiveness.
Neurological complications in children from
either frequent or excessive application of n,
n-dimethylmetatoluamide-containing repellents
have been reported. However, the health risk is
low when these products are used according to
the instructions [177]. n,n-Dimethylmetatolua-
mide should be applied sparingly only to exposed
skin, and not to a child’s face.
Permethrin (synthetic pyrethroid) is an insecti-
cide derived from the chrysanthemum family of
plants. It is used as a spray only on cloth, and it is
deactivated on the skin. Once it is sprayed on to
clothing, it becomes odourless. The effect of one
single application can last for several weeks. Once
it is applied, most ticks which come into contact
with it will curl up, fall off, and eventually die.
Most studies show that transmission of
B. burgdorferi from infected ticks usually requires
a prolonged duration of attachment (12–48 h) to
the host [178]. Therefore, attached ticks should be
removed quickly with the help of medium-tipped
tweezers as close to the skin as possible. If
remnants of bite apparatus remain embedded in
the skin, they should be left there. These are
usually extruded parts, and additional attempts
to remove them often result in unnecessary
damage to tissues, which may increase the risk
of local bacterial infection [136].
Eradication of ticks
In endemic residential areas, clearing bushes and
trees, removing leaf litter and removing wood
piles has been suggested. Pesticides have been
used to suppress the tick population in residential
areas. Erecting fences to exclude deer and ensur-
ing that pets are tick-free may also reduce
exposure to ticks [177].
Vaccines
Vaccines for Lyme disease that use recombinant
OspA (rOspA) as an antigen have been produced
by two manufacturers and field-tested for safety
and efficacy in humans [136]. LYMErix (SmithK-
line Beecham Pharmaceuticals, Philadelphia, PA,
USA) contains 30 mg of purified rOspA lipidated
protein combined with 0.5 mg of aluminium
adjuvant. This is the only licensed Lyme disease
vaccine at this time, but marketing has been
discontinued because of limited demand. Imu-
lyme, a vaccine produced by Pasteur Merieux
Connaught (Swiftwater, PA, USA), which con-
tains 30 mg of purified rOspA lipidated protein
without adjuvant, has not been propagated
further.
rOspA vaccines have a unique mode of action.
OspA is expressed by B. burgdorferi organisms that
reside in the mid-gut of dormant ticks. B. burgdor-
feri subsequently down-regulates the expression in
response to a blood meal and in preparation for
skin invasion. Thus, ticks must become engorged
with blood before they can transmit the organism.
Patients who have not been exposed previously to
B. burgdorferi have little antibody response to OspA
(at least in the early stages of infection). When an
immunised host is bitten by a tick infected with B.
burgdorferi, protective OspA antibodies of the host
are ingested by the tick. These antibodies then
destroy B. burgdorferi in the gut of the tick and thus
prevent transmission to the host.
In a large clinical trial, Steere et al. [179] found
that the efficacy of LYMErix in preventing infec-
tion was 83% in the first year and 100% in the
second year. In another large trial, Sigal et al. [180]
found that the efficacy of the Imulyme vaccine in
preventing symptomatic Lyme disease after the
third injection was 92%. Some of the differences
in the efficacy of the vaccines between the two
studies may be explained by differences in meth-
ods of surveillance. The rOspA vaccines used in
both clinical studies appeared to be safe. The
vaccine-related side effects reported most fre-
quently were pain, redness and swelling at the
sites of injection [136]. These effects were usually
mild and limited. The rOspA vaccine does
not protect all recipients from infection with
B. burgdorferi and provides no protection against
other tick-borne diseases [136]. Therefore, vaccin-
ated persons should also continue to take perso-
nal protective measures against tick bites.
A C K N O W L E D G E M E N T S
The authors would like to thank J. Hacker, M. Frosch and
K. Brehm for continuous support and reading the manuscript.
Singh and Girschick Lyme borreliosis 609
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 598–614
R E F E R E N C E S
1. Orloski KA, Hayes EB, Campbell GL, Dennis DT. Sur-
veillance for Lyme disease—United States, 1992–1998.
MMWR CDC Surveill Summ 2000; 49: 1–11.
2. Stanek G. Lyme disease and related disorders. Microbiol
Sci 1985; 2: 231–234.
3. Fraser CM, Casjens S, Huang WM et al. Genomic
sequence of a Lyme disease spirochaete, Borrelia
burgdorferi. Nature 1997; 390: 580–586.
4. de Silva AM, Fikrig E. Arthropod and host gene expres-
sion by Borrelia burgdorferi. J Clin Invest 1997; 99: 377–379.
5. Anderson JF. Epizootiology of Lyme borreliosis. Scand
J Infect Dis 1991; 77(suppl): 23–34.
6. Piesman J. Standard system for infecting ticks (Acari:
Ixodidae) with the Lyme disease spirochete, Borrelia
burgdorferi. J Med Entomol 1993; 30: 199–203.
7. Wilske B, Steinhuber R, Bergmeister H et al. Lyme
borreliosis in South Germany. Epidemiologic data on the
incidence of cases and on the epidemiology of ticks
(Ixodes ricinus) carrying Borrelia burgdorferi. Dtsch Med
Wochenschr 1987; 112: 1730–1736.
8. Burgdorfer W, Anderson JF, Gern L, Lane RS, Piesman J,
Spielman A. Relationship of Borrelia burgdorferi to its
arthropod vectors. Scand J Infect Dis 1991; 77: 35–40.
9. Aeschlimann A. Development embryonnaire d’Ornith-
odorus moubata et transmission transovarienne de Bor-
relia duttoni. Acta Trop 1958; 15: 15–64.
10. Balashov YS. Transovarial transmission of spirochete
Borrelia sogdiana in Ornithodoros papillipes ticks and its
effect on the biological properties of the agent [in Rus-
sian]. Parazitilogiya 1968; 2: 198–201.
11. Hayes SF, Burgdorfer W, Barbour AG. Bacteriophage in
the Ixodes dammini spirochete, etiological agent of Lyme
disease. J Bacteriol 1983; 154: 1436–1439.
12. Hayes SF, Burgdorfer W. Ultrastructure of Borrelia burg-
dorferi. In: Weber K, Burgdorfer W, eds. Aspects of Lyme
borreliosis. Berlin: Springer, 1993; 29–43.
13. Hans-Walter P, Bettina W, Weber K. Lyme borreliosis:
basic science and clinical aspects. Lancet 1994; 343: 1013–
1016.
14. Norris SJ, Carter CJ, Howell JK, Barbour AG. Low-pas-
sage-associated proteins of Borrelia burgdorferi B31: char-
acterization and molecular cloning of OspD, a surface-
exposed, plasmid-encoded lipoprotein. Infect Immun
1992; 60: 4662–4672.
15. Lam TT, Nguyen TP, Montgomery RR, Kantor FS, Fikrig
E, Flavell RA. Outer surface proteins E and F of Borrelia
burgdorferi, the agent of Lyme disease. Infect Immun 1994;
62: 290–298.
16. Umemoto T, Namikawa I. Electron microscopy of the
spherical body of oral spirochetes in vitro. Further stud-
ies. Microbiol Immunol 1980; 24: 321–334.
17. Barbour AG, Hayes SF. Biology of Borrelia species.
Microbiol Rev 1986; 50: 381–400.
18. Kersten A, Poitscheck S, Rauch S, Aberer E. Effects of
penicillin, ceftriaxone and doxycycline on morphology of
Borrelia burgdorferi. Antimicrob Agents Chemother 1995; 39:
1127–1133.
19. Preac Mursic V, Weber K, Pfister HW et al. Formation and
cultivation of Borrelia burgdorferi spheroplast 1-form
variants. Infection 1989; 17: 355–359.
20. Garon CF, Dorward DW, Corwin MD. Structural features
of Borrelia burgdorferi—the Lyme disease spirochete: silver
staining for nucleic acids. Scanning Microsc 1989; 3(suppl):
109–115.
21. Alban SP, Paul W, Johnson PW, Nelson DR. Serum star-
vation induced changes in protein synthesis and mor-
phology of Borrelia burgdorferi. Microbiology 2000; 146:
119–127.
22. Brorson O, Brorson SH. In vitro conversion of Borrelia
burgdorferi to cystic forms in spinal fluid, and transfor-
mation to mobile spirochetes by incubation in BSK-H
media. Infection 1998; 26: 144–150.
23. Aberer E, Koszik F, Silberer M. Why is chronic Lyme
borreliosis chronic? Clin Infect Dis 1997; 25: S64–S70.
24. Hulinska D, Bartak P, Hercogova J, Hancil J, Basta J,
Schramlova J. Electron microscopy of Langerhans cells
and Borrelia burgdorferi in Lyme disease patients. Zentralbl
Bakteriol 1994; 280: 348–359.
25. Holt SC. Anatomy and chemistry of spirochetes. Microbiol
Rev 1978; 42: 114–160.
26. Hovind-Hougen K. Treponema and Borrelia morphology.
In: Johnson RC, ed. The biology of parasitic spirochetes. New
York: Academic Press, 1976; 7–28.
27. Lofgren R, Soule MH. The structure of Spirochaetea novyi
as revealed by electron microscopy. Bacteriology 1945; 50:
679–690.
28. Hovind-Hougen K. Ultrastructure of spirochetes isolated
from Ixodes ricinus and Ixodes dammini. Yale J Biol Med
1984; 57: 543–548.
29. Hovind-Hougen K. Determination by means of electron
microscopy of morphologic criteria of value for clarifi-
cation of some spirochetes in particular treponemes. Acta
Pathol Mirobiol Scand 1976; 255(suppl B): 1–41.
30. Barbour G, Hayes SF, Heiland RA, Schrumpf ME, Tessier
SL. A Borrelia genus specific monoclonal antibody binds
to a flagellar epitope. Infect Immun 1986; 52: 549–554.
31. Ginger CD. Isolation and characterization of muramic
acid from two spirochetes: Borrelia duttoni and Leptospira
biflexa. Nature 1963; 199: 159.
32. Klaviter EC, Johnson RC. Isolation of the outer envelope,
chemical components, and ultrastructure of Borrelia her-
msi grown in vitro. Acta Trop 1979; 36: 123–131.
33. Barbour AG, Schrumpf ME. Polymorphism of the major
surface proteins of Borrelia burgdorferi. Zentrabl Bakteriol
Hyg 1986; 263: 83–91.
34. Schaible UE, Kramer MD, Eichmann K, Modolell M,
Museteanu C, Simon MM. Monoclonal antibodies specific
for the outer surface protein (OspA) prevent Lyme bor-
reliosis in severe combined immunodeficiency (SCID).
Proc Natl Acad Sci USA 1990; 87: 3768–3772.
35. Preac-Mursic V, Wilske B, Patsouris E et al. Active
immunization with pC protein of Borrelia burgdorferi
protects gerbils against B. burgdorferi infection. Infection
1992; 20: 342–349.
36. Burkot TR, Piesman J, Wirt RA. Quantitation of Borrelia
burgdorferi outer surface protein A in Ixodes scapularis.
Fluctuations during the tick life cycle, doubling times and
loss while feeding. J Infect Dis 1994; 170: 883–889.
37. Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA.
Induction of an outer surface protein on Borrelia burg-
dorferi during tick feeding. Proc Natl Acad Sci USA 1995;
92: 2909–2913.
610 Clinical Microbiology and Infection, Volume 10 Number 7, July 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 598–614
38. Montgomery RR, Malawista SE, Feen KJ, Bockenstedt LK.
Direct demonstration of antigenic substitution of Borrelia
burgdorferi ex vivo: exploration of the paradox of the early
immune response to outer surface proteins A and C in
Lyme disease. J Exp Med 1996; 183: 261–269.
39. Obonyo M, Munderloh UG, Fingerle V, Wilske B, Kurtti
TJ. Borrelia burgdorferi in tick cell culture modulates
expression of outer surface proteins A and C in response
to temperature. J Clin Microbiol 1999; 37: 2137–2141.
40. Stevenson B, Schwan TG, Rosa PA. Temperature-related
differential expression of antigens in the Lyme disease
spirochete, Borrelia burgdorferi. Infect Immun 1995; 63:
4535–4539.
41. Stevenson B, Tilly K, Rosa PA. A family of genes located
on four separate 32-kilobase circular plasmids in Borrelia
burgdorferi B31. J Bacteriol 1996; 178: 3508–3516.
42. Zhang JR, Norris SJ. Genetic variation of the Borrelia
burgdorferi gene vlse involves cassette specific, segmental
gene conversion. Infect Immun 1998; 66: 3698–3704.
43. Steere AC. Lyme disease. N Engl J Med 1989; 321: 586–596.
44. Weber K, Pfister HW, Reimers CD. Clinical features of
Lyme borreliosis: clinical overview. In: Weber K, Burg-
dorfer W, eds. Aspects of Lyme borreliosis. Berlin: Springer,
1993; 93–104.
45. Hengge UR, Tannapfel A, Tyring SK, Erbel R, Arendt G,
Ruzicka T. Lyme borreliosis. Lancet Infect Dis 2003; 3: 489–
500.
46. Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala
I. Late Lyme borreliosis: epidemiology, diagnosis and
clinical features. Ann Med 1993; 25: 349–352.
47. Strle F, Nadelman RB, Cimperman J et al. Comparison of
culture-confirmed erythema migrans caused by Borrelia
burgdorferi sensu stricto in New York State and by Borrelia
afzelii in Slovenia. Ann Intern Med 1999; 130: 32–36.
48. Wormser GP, Bittker S, Cooper D, Nowakowski J,
Nadelman RB, Pavia C. Comparison of the yields of
blood cultures using serum or plasma from patients with
early Lyme disease. J Clin Microbiol 2000; 38: 1648–1650.
49. Stanek G, O’Connell S, Cimmino M et al. European Union
Concerted Action on Risk Assessment in Lyme Borrelio-
sis: clinical case definitions for Lyme borreliosis. Wien
Klin Wochenschr 1996; 108: 741–747.
50. Picken RN, Strle F, Ruzic-Sabljic E et al. Molecular sub-
typing of Borrelia burgdorferi sensu lato isolates from five
patients with solitary lymphocytoma. J Invest Dermatol
1997; 108: 92–97.
51. Roberts ED, Bohm RP, Lowrie RC et al. Pathogenesis of
Lyme neuroborreliosis in the rhesus monkey: the early
disseminated and chronic phases of disease in the
peripheral nervous system. J Infect Dis 1998; 178: 722–
732.
52. Cadavid D, O’Neill T, Schaefer H, Pachner AR. Local-
ization of Borrelia burgdorferi in the nervous system and
other organs in a nonhuman primate model of lyme
disease. Lab Invest 2000; 80: 1043–1054.
53. Stanek G, Klein J, Bittner R, Glogar D. Isolation of Borrelia
burgdorferi from the myocardium of a patient with
longstanding cardiomyopathy. N Engl J Med 1990; 322:
249–252.
54. Steere AC, Duray PH, Butcher EC. Spirochetal antigens
and lymphoid cell surface markers in Lyme synovitis.
Comparison with rheumatoid synovium and tonsillar
lymphoid tissue. Arthritis Rheum 1988; 31: 487–495.
55. Rothermel H, Hedges TR, Steere AC. Optic neuropathy in
children with Lyme disease. Pediatrics 2001; 108: 477–481.
56. Oschmann P, Dorndorf W, Hornig C, Schafer C, Wel-
lensiek HJ, Pflughaupt KW. Stages and syndromes of
neuroborreliosis. J Neurol 1998; 245: 262–272.
57. Logigian EL, Steere AC. Clinical and electrophysiologic
findings in chronic neuropathy of Lyme disease. Neurol-
ogy 1992; 42: 303–311.
58. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic
manifestations of Lyme disease. N Engl J Med 1990; 323:
1438–1444.
59. Halperin JJ, Luft BJ, Anand AK et al. Lyme neuroborrel-
iosis: central nervous system manifestations. Neurology
1989; 39: 753–759.
60. Halperin JJ. Lyme disease and the peripheral nervous
system. Muscle Nerve 2003; 28: 133–143.
61. Logigian EL, Kaplan RF, Steere AC. Successful treatment
of Lyme encephalopathy with intravenous ceftriaxone.
J Infect Dis 1999; 180: 377–383.
62. Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL.
Lyme disease in children in southeastern Connecticut.
Pediatric Lyme Disease Study Group. N Engl J Med 1996;
335: 1270–1274.
63. Strobino BA, Williams CL, Abid S, Chalson R, Spierling P.
Lyme disease and pregnancy outcome: a prospective
study of two thousand prenatal patients. Am J Obstet
Gynecol 1993; 169: 367–374.
64. Nadal D, Hunziker UA, Bucher HU, Hitzig WH, Duc G.
Infants born to mothers with antibodies against Borrelia
burgdorferi at delivery. Eur J Pediatr 1989; 148: 426–427.
65. Williams CL, Strobino B, Weinstein A, Spierling P, Medici
F. Maternal Lyme disease and congenital malformations:
a cord blood serosurvey in endemic and control areas.
Paediatr Perinat Epidemiol 1995; 9: 320–330.
66. Strobino B, Abid S, Gewitz M. Maternal Lyme disease
and congenital heart disease: a case-control study in an
endemic area. Am J Obstet Gynecol 1999; 180: 711–716.
67. Elliott DJ, Eppes SC, Klein JD. Teratogen update: Lyme
disease. Teratology 2001; 64: 276–281.
68. Culp RW, Eichenfield AH, Davidson RS, Drummond DS,
Christofersen MR, Goldsmith DP. Lyme arthritis in chil-
dren. An orthopaedic perspective. J Bone Joint Surg Am
1987; 69: 96–99.
69. Eichenfield AH, Goldsmith DP, Benach JL et al. Child-
hood Lyme arthritis: experience in an endemic area.
J Pediatr 1986; 109: 753–758.
70. Eppes SC, Nelson DK, Lewis LL, Klein JD. Characteri-
zation of Lyme meningitis and comparison with viral
meningitis in children. Pediatrics 1999; 103: 957–960.
71. Huppertz HI, Munchmeier D, Lieb W. Ocular manifes-
tations in children and adolescents with Lyme arthritis.
Br J Ophthalmol 1999; 83: 1149–1152.
72. Lesser RL, Kornmehl EW, Pachner AR et al. Neuro-oph-
thalmologic manifestations of Lyme disease. Ophthalmo-
logy 1990; 97: 699–706.
73. Farris BK, Webb RM. Lyme disease and optic neuritis.
J Clin Neuroopthalmol 1988; 8: 73–78.
74. Scott IU, Silva-Lepe A, Siatkowski RM. Chiasmal optic
neuritis in Lyme disease. Am J Ophthalmol 1997; 123: 136–
138.
75. Winward KE, Smith JL. Ocular disease in Caribbean pa-
tients with serologic evidence of Lyme borreliosis. J Clin
Neuroophthalmol 1989; 9: 65–70.
Singh and Girschick Lyme borreliosis 611
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 598–614
76. Bentas W, Karch H, Huppertz HI. Lyme arthritis in
children and adolescents: outcome 12 months after initi-
ation of antibiotic therapy. J Rheumatol 2000; 27: 2025–2030.
77. Huppertz HI. Lyme disease in children. Curr Opin
Rheumatol 2001; 13: 434–440.
78. Steere AC, Schoen RT, Taylor E. The clinical evolution of
Lyme arthritis. Ann Intern Med 1987; 107: 725–731.
79. Zemel LS. Lyme disease—a pediatric perspective.
J Rheumatol 1992; 34(suppl): 1–13.
80. Fraser CM, Norris SJ, Weinstock GM et al. Complete
genome sequence of Treponema pallidum, the syphilis
spirochete. Science 1998; 281: 375–388.
81. Bunkis J, Barbour AG. Access of antibody or trypsin to
an integral outer membrane protein (P66) of Borrelia
burgdorferi is hindered by Osp lipoproteins. Infect Immun
1999; 67: 2874–2883.
82. Sadziene A, Barbour AG. Growth inhibition of Borrelia
burgdorferi sensu lato by antibodies. A contribution to
understanding the pathogenesis and improving diagno-
sis of Lyme borreliosis. Wien Med Wochenschr 1995; 145:
162–165.
83. Seinost G, Dykhuizen DE, Dattwyler RJ et al. Four clones
of Borrelia burgdorferi sensu stricto cause invasive infection
in humans. Infect Immun 1999; 67: 3518–3524.
84. Coleman JL, Gebbia JA, Piesman J, Degen JL, Bugge TH,
Benach JL. Plasminogen is required for efficient dissem-
ination of B. burgdorferi in ticks and for enhancement of
spirochetemia in mice. Cell 1997; 89: 1111–1119.
85. Coburn J, Magoun L, Bodary SC, Leong JM. Integrins
alpha(v)beta3 and alpha5beta1 mediate attachment of
Lyme disease spirochetes to human cells. Infect Immun
1998; 66: 1946–1952.
86. Guo BP, Brown EL, Dorward DW, Rosenberg LC, Hook
M. Decorin binding adhesions from Borrelia burgdorferi.
Mol Microbiol 1998; 30: 711–723.
87. Probert WS, Johnson BJ. Identification of a 47 kDa fibro-
nectin-binding protein expressed by Borrelia burgdorferi
isolate B31. Mol Microbiol 1998; 30: 1003–1015.
88. Guo BP, Norris SJ, Rosenberg LC, Hook M. Adherence of
Borrelia burgdorferi to proteoglycan decorin. Infect Immun
1995; 63: 3467–3472.
89. Feng S, Hodzic E, Stevenson B, Barthold SW. Humoral
immunity to Borrelia burgdorferi N40 decorin binding
proteins during infection of laboratory mice. Infect Immun
1998; 66: 2827–2835.
90. Skare JT, Foley DM, Hernandez SR et al. Cloning and
molecular characterization of plasmid-encoded antigens
of Borrelia burgdorferi. Infect Immun 1999; 67: 4407–4417.
91. Hagman KE, Lahdenne P, Popova TG et al. Decorin-
binding protein of Borrelia burgdorferi is encoded within a
two-gene operon and is protective in the murine model of
Lyme borreliosis. Infect Immun 1998; 66: 2674–2683.
92. Brown EL, Wooten RM, Johnson BJ et al. Resistance to
Lyme disease in decorin-deficient mice. J Clin Invest 2001;
107: 845–852.
93. Silberer M, Koszik F, Stingl G, Aberer E. Downregulation
of class II molecules on epidermal Langerhans cells in
Lyme borreliosis. Br J Dermatol 2000; 143: 786–794.
94. Sellati TJ, Burns MJ, Ficazzola MA, Furie MB. Borrelia
burgdorferi upregulates expression of adhesion molecules
on endothelial cells and promotes transendothelial
migration of neutrophils in vitro. Infect Immun 1995; 63:
4439–4447.
95. Leong JM, Morrissey PE, Ortega-Barria E, Pereira ME,
Coburn J. Hemagglutination and proteoglycan binding
by the Lyme disease spirochete, Borrelia burgdorferi. Infect
Immun 1995; 63: 874–883.
96. Kopp PA, Schmitt M, Wellensiek HJ, Blobel H. Isolation
and characterization of fibronectin-binding sites of Bor-
relia garinii N34. Infect Immun 1995; 63: 3804–3808.
97. Guner ES. Complement evasion by the Lyme disease
spirochete Borrelia burgdorferi grown in host-derived tis-
sue co-cultures: role of fibronectin in complement-resist-
ance. Experientia 1996; 52: 364–372.
98. Comstock L, Thomas DD. Characterization of Borrelia
burgdorferi invasion of cultured endothelial cells. Microb
Pathog 1991; 10: 137–148.
99. Girschick HJ, Meister S, Karch H, Huppertz HI. Borrelia
burgdorferi downregulates ICAM-1 on human synovial
cells in vitro. Cell Adhes Commun 1999; 7: 73–83.
100. Girschick HJ, Huppertz HI, Russmann H, Krenn V, Karch
H. Intracellular persistence of Borrelia burgdorferi in hu-
man synovial cells. Rheumatol Int 1996; 16: 125–132.
101. Gross DM, Forsthuber T, Tary-Lehmann M et al. Identi-
fication of LFA-1 as a candidate autoantigen in treatment-
resistant Lyme arthritis. Science 1998; 281: 703–706.
102. Steere AC, Gross D, Meyer AL, Huber BT. Autoimmune
mechanisms in antibiotic treatment-resistant Lyme arth-
ritis. J Autoimmun 2001; 16: 263–268.
103. Krause A, Brade V, Schoerner C, Solbach W, Kalden JR,
Burmester GR. T cell proliferation induced by Borrelia
burgdorferi in patients with Lyme borreliosis. Autologous
serum required for optimal stimulation. Arthritis Rheum
1991; 34: 393–402.
104. Neumann A, Schlesier M, Schneider H, Vogt A, Peter
HH. Frequencies of Borrelia burgdorferi-reactive T
lymphocytes in Lyme arthritis. Rheumatol Int 1989; 9: 237–
241.
105. Roessner K, Fikrig E, Russel JQ, Cooper SM, Favell RA,
Budd RC. Prominent T lymphocyte response to Borrelia
burgdorferi from peripheral blood of unexposed donors.
Eur J Immunol 1994; 24: 320–324.
106. Wallach FR, Murray HW. Lymphocyte proliferation as-
say in Lyme disease. J Infect Dis 1992; 166: 938–939.
107. Zoschke DC, Skemp AA, Defosse DL. Lymphoprolifera-
tive responses to Borrelia burgdorferi in Lyme disease. Ann
Intern Med 1991; 114: 285–289.
108. Huppertz HI, Mosbauer S, Busch DH, Karch H.
Lymphoproliferative responses to Borrelia burgdorferi in
the diagnosis of Lyme arthritis in children and adoles-
cents. Eur J Pediatr 1996; 155: 297–302.
109. Rutkowski S, Busch DH, Huppertz HI. Lymphocyte
proliferation assay in response to Borrelia burgdorferi in
patients with Lyme arthritis: analysis of lymphocyte
subsets. Rheumatol Int 1997; 17: 151–158.
110. Lengl-Janssen B, Strauss AF, Steere AC, Kamradt T. The T
helper cell response in Lyme arthritis: differential recog-
nition of Borrelia burgdorferi outer surface protein A in
patients with treatment-resistant or treatment-responsive
Lyme arthritis. J Exp Med 1994; 180: 2069–2078.
111. Yoshinari NH, Reinhardt BN, Steere AC. T cell responses
to polypeptide fractions of Borrelia burgdorferi in patients
with Lyme arthritis. Arthritis Rheum 1991; 34: 707–713.
112. Yssel H, Nakamoto T, Schneider P et al. Analysis of T
lymphocytes cloned from synovial fluid and blood of a
612 Clinical Microbiology and Infection, Volume 10 Number 7, July 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 598–614
patient with Lyme arthritis. Int Immunol 1990; 2: 1081–
1089.
113. Yssel H, Shanafelt MC, Soderberg C, Schneider PV, An-
zola J, Pelty G. Borrelia burgdorferi activates a T helper
type 1-like cell subset in Lyme arthritis. J Exp Med 1991;
174: 593–601.
114. Lim LC, England DM, DuChateau BK, Glowacki NJ,
Schell RF. Borrelia burgdorferi-specific T lymphocytes in-
duce severe destructive Lyme arthritis. Infect Immun 1995;
63: 1400–1408.
115. Matyniak JE, Reiner SL. T helper phenotype and genetic
susceptibility in experimental Lyme disease. J Exp Med
1995; 181: 1251–1254.
116. Busch DH, Jassoy C, Brinckmann U, Girschick H, Hup-
pertz HI. Detection of Borrelia burgdorferi-specific CD8+
cytotoxic T cells in patients with Lyme arthritis. J Immunol
1996; 157: 3534–3541.
117. Gross DM, Huber BT. Cellular and molecular aspects of
Lyme arthritis. Cell Mol Life Sci 2000; 57: 1562–1569.
118. de Souza MS, Smith AL, Beck DS, Terwilliger GA, Fikrig
E, Barthold SW. Long term study of cell mediated
responses to Borrelia burgdorferi in the laboratory mouse.
Infect Immun 1993; 61: 1814–1822.
119. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western
blotting in the serodiagnosis of Lyme disease. J Infect Dis
1993; 167: 392–400.
120. Huppertz HI, Bohme M, Standaert SM, Karch H, Plotkin
SA. Incidence of Lyme borreliosis in the Wurzburg region
of Germany. Eur J Clin Microbiol Infect Dis 1999; 18: 697–
703.
121. Hobusch D, Christen HJ, Huppertz HI, Noack R. Diag-
nosis and therapy of Lyme borreliosis in children. Prac-
tice guideline of the German Society for Pediatric
Infectious Diseases. Klin Padiatr 1999; 211: 70–74.
122. Steere AC. Lyme disease. N Engl J Med 2001; 345: 115–125.
123. Huppertz HI, Karch H, Suschke HJ et al. Lyme arthritis in
European children and adolescents. The Pediatric Rheu-
matology Collaborative Group. Arthritis Rheum 1995; 38:
361–368.
124. Paul WE. Fundamental immunology. New York: Raven
Press, 1993.
125. Du Chateau BK, England DM, Callister SM, Lim LC,
Lovrich SD, Schell RF. Macrophages exposed to Borrelia
burgdorferi induce Lyme arthritis in hamsters. Infect Im-
mun 1996; 64: 2540–2547.
126. DuChateau BK, Jensen JR, England DM, Callister SM,
Lovrich SD, Schell RF. Macrophages and enriched pop-
ulations of T lymphocytes interact synergistically for the
induction of severe, destructive Lyme arthritis. Infect
Immun 1997; 65: 2829–2836.
127. Beck G, Benach JL, Habicht GS. Isolation of interleukin 1
from joint fluids of patients with Lyme disease. J Rheu-
matol 1989; 16: 800–806.
128. De-Fosse DL, Johnson RC. In-vitro and in-vivo induction
of tumor necrosis factor alpha by Borrelia burgdorferi. In-
fect Immunol 1992; 60: 1109–1113.
129. Miller LC, Lynch EA, Isa S, Logan JW, Dinareloo CA,
Steere AC. Balance of synovial fluid interleukin-1beta and
interleukin-1 receptor antagonist and recovery from
Lyme arthritis. Lancet 1993; 341: 146–148.
130. Steere AC, Brinckerhoff CE, Miller DJ, Drinker H, Harris
AD, Malaista SE. Elevated levels of collagenase and
prostaglandin E2 from synovium associated with erosion
of cartilage and bone in a patient with chronic Lyme
arthritis. Arthritis Rheum 1980; 23: 591–599.
131. Bertolini DR, Nedwin GE, Bringman TS, Smith DD,
Mundy GR. Stimulation of bone resorption and inhibition
of bone formation in-vitro by human tumor necrosis fac-
tors. Nature 1986; 319: 516–518.
132. Ma Y, Seiler KP, Tai K, Yang L, Woods M, Weis JJ. Outer
surface lipoproteins of Borrelia burgdorferi stimulate nitric
oxide production by the cytokine inducible pathway.
Infect Immun 1994; 62: 3663–3671.
133. McCartney-Francis N, Allen JB, Mizel DE et al. Suppres-
sion of arthritis by an inhibitor of nitric oxide synthase.
J Exp Med 1993; 178: 749–754.
134. Weinberg JB, Granger DL, Pisetsky DS et al. The role of
nitric oxide in the pathogenesis of spontaneous murine
autoimmune disease: increased nitric oxide production
and nitric oxide synthase expression in MRL-lpr ⁄ lpr
mice, and reduction of spontaneous glomerulonephritis
and arthritis by orally administered NG-monomethyl-
L-arginine. J Exp Med 1994; 179: 651–660.
135. Gajdusek DC. Hypothesis: interference with axonal
transport of neurofilament as a common pathogenetic
mechanism in certain diseases of the central nervous
system. N Engl J Med 1985; 312: 714–719.
136. Shapiro ED, Gerber MA. Lyme disease. Clin Infect Dis
2000; 31: 533–542.
137. Steere AC, Dwyer E, Winchester R. Association of chronic
Lyme arthritis with HLA-DR4 and HLA-DR2 alleles.
N Engl J Med 1990; 323: 219–223.
138. Kalish RA, Leong JM, Steere AC. Early and late antibody
responses to full-length and truncated constructs of outer
surface protein A of Borrelia burgdorferi in Lyme disease.
Infect Immun 1995; 63: 2228–2235.
139. Kamradt T, Krause A, Burmester GR. A role for T cells in
the pathogenesis of treatment-resistant Lyme arthritis.
Mol Med 1995; 1: 486–490.
140. Nepom GT, Erlich H. MHC class-II molecules and auto-
immunity. Ann Rev Immunol 1991; 9: 493–525.
141. Kalish RA, Leong JM, Steere AC. Association of treat-
ment-resistant chronic Lyme arthritis with HLA-DR4 and
antibody reactivity to OspA and OspB of Borrelia burg-
dorferi. Infect Immun 1993; 61: 2774–2779.
142. Steere AC, Baxter-Lowe LA. Association of chronic,
treatment resistant Lyme arthritis with rheumatoid arth-
ritis (RA) alleles. Arthritis Rheum 1998; 41: S81.
143. Benach JL, Fleit HB, Habicht GS, Coleman JL, Bosler EM,
Lane BP. Interactions of phagocytes with the Lyme dis-
ease spirochete: role of the Fc receptor. J Infect Dis 1984;
150: 497–507.
144. Benach JL, Habicht GS, Gocinski BL, Coleman JL. Phag-
ocytic cell responses to in vivo and in vitro exposure to
the Lyme disease spirochete. Yale J Biol Med 1984; 57: 599–
605.
145. Georgilis K, Noring R, Steere AC, Klempner MS. Neu-
trophil chemotactic factors in synovial fluids of patients
with Lyme disease. Arthritis Rheum 1991; 34: 770–775.
146. Montgomery RR, Nathanson MH, Malawista SE. The fate
of Borrelia burgdorferi, the agent for Lyme disease, in
mouse macrophages. Destruction, survival, recovery.
J Immunol 1993; 150: 909–915.
147. Peterson PK, Clawson CC, Lee DA, Garlich DJ, Quie PG,
Johnson RC. Human phagocyte interactions with the
Lyme disease spirochete. Infect Immun 1984; 46: 608–611.
Singh and Girschick Lyme borreliosis 613
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 598–614
148. Montgomery RR, Malawista SE. Entry of Borrelia burg-
dorferi into macrophages is end-on and leads to degra-
dation in lysosomes. Infect Immun 1996; 64: 2867–2872.
149. Hechemy KE, Samsonoff WA, Harris HL, McKee M.
Adherence and entry of Borrelia burgdorferi in Vero cells.
J Med Microbiol 1992; 36: 229–238.
150. Filgueiria L, Nestle FO, Rittig M, Joller HI, Groscurth P.
Human dendritic cells phagocytose and process Borrelia
burgdorferi. J Immunol 1996; 157: 2998–3005.
151. Gross D, Huber BT, Steere AC. Molecular mimicry and
Lyme arthritis. Curr Dir Autoimmun 2001; 3: 94–111.
152. Klempner MS, Huber BT. Is it thee or me?—autoimmu-
nity in Lyme disease. Nat Med 1999; 5: 1346–1347.
153. Trollmo C, Meyer AL, Steere AC, Hafler DA, Huber BT.
Molecular mimicry in Lyme arthritis demonstrated at the
single cell level: LFA-1 alpha L is a partial agonist for
outer surface protein A-reactive T cells. J Immunol 2001;
166: 5286–5291.
154. Hemmer B, Gran B, Zhao Y et al. Identification of candi-
date T-cell epitopes and molecular mimics in chronic
Lyme disease. Nat Med 1999; 5: 1375–1382.
155. Modolell M, Schaible UE, Rittig M, Simon MM. Killing of
Borrelia burgdorferi by macrophages is dependent on
oxygen radicals and nitric oxide and can be enhanced by
antibodies to outer surface proteins of the spirochete.
Immunol Lett 1994; 40: 139–146.
156. Rittig MG, Krause A, Haupl T et al. Coiling phagocytosis
is the preferential phagocytic mechanism for Borrelia
burgdorferi. Infect Immun 1992; 60: 4205–4212.
157. Szczepanski A, Fleit HB. Interaction between Borrelia
burgdorferi and polymorphonuclear leukocytes. Phago-
cytosis and the induction of respiratory burst. Ann NY
Acad Sci 1988; 539: 425–428.
158. Rittig MG, Haupl T, Burmester GR. Coiling phagocytosis:
a way for MHC class I presentation of bacterial antigens?
Int Arch Allergy Immunol 1994; 103: 4–10.
159. Klempner MS, Noring R, Rogers RA. Invasion of human
skin fibroblasts by the Lyme disease spirochete, Borrelia
burgdorferi. J Infect Dis 1993; 167: 1074–1081.
160. Ma Y, Sturrock A, Weis JJ. Intercellular localization of
Borrelia burgdorferi within human endothelial cell. Infect
Immunol 1991; 59: 671–678.
161. Coyle PK, Goodman JL, Krupp LB, Loggiau EL, Reik L.
Lyme disease: continuum: lifelong learning in neurology,
Vol. 5. Philadelphia: Lippincott Williams & Wilkins, 1999.
162. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH,
Steere AC. Detection of Borrelia burgdorferi by polymerase
chain reaction in synovial fluid from patients with Lyme
arthritis. N Engl J Med 1994; 330: 229–234.
163. Nocton JJ, Bloom BJ, Rutledge BJ et al. Detection of Bor-
relia burgdorferi DNA by polymerase chain reaction in
cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis
1996; 174: 623–627.
164. Wilske B, Preac-Mursic V. Microbial diagnosis of Lyme
borreliosis. In: Weber K, Burgdorfer W, eds. Aspects of
Lyme borreliosis. Berlin: Springer, 1993; 267–300.
165. Robertson J, Guy E, Andrews N et al. A European
multicenter study of immunoblotting in serodiagnosis of
Lyme borreliosis. J Clin Microbiol 2000; 38: 2097–2102.
166. Wilske B, Habermann C, Fingerle V et al. An improved
recombinant IgG immunoblot for serodiagnosis of Lyme
borreliosis. Med Microbiol Immunol (Berl) 1999; 188: 139–
144.
167. Schutzer SE, Coyle PK, Reid P, Holland B. Borrelia burg-
dorferi-specific immune complexes in acute Lyme disease.
JAMA 1999; 282: 1942–1946.
168. Grodzicki RL, Steere AC. Comparison of immunoblotting
and indirect enzyme-linked immunosorbent assay using
different antigen preparations for diagnosing early Lyme
disease. J Infect Dis 1988; 157: 790–797.
169. Lahdenne P, Panelius J, Saxen H et al. Improved serodi-
agnosis of erythema migrans using novel recombinant
borrelial BBK32 antigens. J Med Microbiol 2003; 52: 563–
567.
170. Krause PJ, Telford SR, Spielman A et al. Concurrent Lyme
disease and babesiosis. Evidence for increased severity
and duration of illness. JAMA 1996; 275: 1657–1660.
171. Halperin JJ, Logigian EL, Finkel MF, Pearl RA. Practice
parameters for the diagnosis of patients with nervous
system Lyme borreliosis (Lyme disease). Quality Stand-
ards Subcommittee of the American Academy of Neur-
ology. Neurology 1996; 46: 619–627.
172. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treat-
ment of late Lyme borreliosis—randomised comparison
of ceftriaxone and penicillin. Lancet 1988; 1: 1191–1194.
173. Dinerman H, Steere AC. Lyme disease associated with
fibromyalgia. Ann Intern Med 1992; 117: 281–285.
174. Kalish RA, Kaplan RF, Taylor E, Jones-Woodward L,
Workman K, Steere AC. Evaluation of study patients with
Lyme disease, 10–20-year follow-up. J Infect Dis 2001; 183:
453–460.
175. Wormser GP, Nadelman RB, Dattwyler RJ et al. Practice
guidelines for the treatment of Lyme disease. The Infec-
tious Diseases Society of America. Clin Infect Dis 2000;
31(suppl 1): 1–14.
176. Shapiro ED. Lyme disease. Pediatr Rev 1998; 19: 147–154.
177. Brown M, Hebert AA. Insect repellent: an overview. J Am
Acad Dermatol 1997; 36: 243–249.
178. Piesman J, Oliver JR, Sinsky RJ. Growth kinetics of the
Lyme disease spirochete (Borrelia burgdorferi) in vector
ticks (Ixodes dammini). Am J Trop Med Hyg 1990; 42: 352–
357.
179. Steere AC, Sikand VK, Meurice F et al. Vaccination
against Lyme disease with recombinant Borrelia burgdor-
feri outer-surface lipoprotein A with adjuvant. Lyme
Disease Vaccine Study Group. N Engl J Med 1998; 339:
209–215.
180. Sigal LH, Zahradnik JM, Lavin P et al. A vaccine con-
sisting of recombinant Borrelia burgdorferi outer-surface
protein A to prevent Lyme disease. Recombinant Outer-
Surface Protein A Lyme Disease Vaccine Study Consor-
tium. N Engl J Med 1998; 339: 216–222.
614 Clinical Microbiology and Infection, Volume 10 Number 7, July 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 598–614
